Non-invasive and radiation-free assessment for early rule-out of significant CAD.
CADScor®System: Overview
An advanced acoustic-based diagnostic aid to easily and quickly rule out significant coronary artery disease at point of care.*
Use CADScor®System to Determine if Chest Pain is Related to the Heart*
CADScor®System is a point-of-care diagnostic aid that uses highly sensitive acoustics and advanced computational processing to analyze the patient's coronary blood flow. The system calculates a patient-specific CAD-score, and couples it with risk factors to rapidly indicate the patient’s risk of significant coronary stenosis for immediate risk stratification, prior to potential secondary evaluation.2 CADScor®System has been used in over 29,000 patient assessments 3 and has CE-marking and FDA De Novo clearance.
CADScor®System Uses Ultra-Sensitive Acoustics and AI to Rapidly Rule-Out Significant Coronary Artery Disease in 10 Minutes¹*
Can help save costs of more advanced CAD diagnostics in up to 35% of patients.²
Rapid and easy-to-use, with clear results in 10 minutes.
An Individual CAD-score Indicates Low or Elevated Significant CAD Risk in Patients
The CAD-score is based on a phonocardiographic assessment, AI-powered calculations and risk factors.¹
Low Risk
Significant CAD rule-out in 35% of patients². Seek alternative diagnosis for symptoms.
Elevated Risk
Significant CAD cannot be ruled out. Refer for further diagnostics.
CADScor®System Research, Development and Clinical Studies
CADScor®System is approved in Europe with CE-marking and has received FDA De Novo clearance as a diagnostic aid for symptomatic patients with suspected CAD. Multiple clinical studies have been published to demonstrate CADScor®System’s performance.
Physicians’ Experiences Using CADScor®System
Explore customer feedbackSchedule a demo of the CADScor®System
Schedule a free demo of CADScor®System and learn how you can rule out significant CAD patients in 10 minutes.*
- Winther S, et al. Heart 2018;104:928–935 (Dan-NICAD I)
- User manual US-FDA v.12.Y, prevalence 10,7%
- Based on commercial patch use since 2017